The Management

Mark S. Duxon PhD

mark_duxon_400Mark joined Transpharmation in late 2011 as CEO following several years working as a CEO of preclinical/translational Contract Research Organisations (e.g. Porsolt (France), Maccine (Singapore)).

Mark joined Transpharmation in late 2011 as CEO following several years working as a CEO of preclinical/translational Contract Research Organisations (e.g. Porsolt (France), Maccine (Singapore)). Mark is an experienced international commercial leader with a track record of growing drug discovery and pharma service businesses via organic growth and through raising capital. He has several Non-Executive Director positions and recently founded Varsity Biologisitcs to provide sample shipment support to the global pharma industry. Mark is a Molecular Biologist and Neuropharmacologist by training, obtaining his PhD at the University of Nottingham before embarking on a career in several major Pharma companies including GSK. He has lead several Drug Discovery programmes into preclinical development across Psychiatric and Neurological therapeutic areas and has worked extensively in the product support of the antidepressant Paxil/Seroxat (paroxetine). Mark, set up and established GSK’s Center for Cognitive and Neurodegenerative Disease in Singapore in 2003.

Neil Upton PhD

Prior to setting up Transpharmation in 2010, Neil gained extensive drug discovery know-how working for over 25 years in major Pharma companies (SmithKline Beecham, GlaxoSmithKline)

Prior to setting up Transpharmation in 2010, Neil gained extensive drug discovery know-how working for over 25 years in major Pharma companies (SmithKline Beecham, GlaxoSmithKline). This involved leading multidisciplinary teams of up to 40 preclinical and clinical translational scientists specializing in diverse CNS and GI indications. He has been the strategic leader on several portfolios including Alzheimer’s disease, schizophrenia, pain, epilepsy and sleep disorders. Neil has taken molecules directed to numerous targets through Discovery and into clinical trials. These include 5-HT6, H3 and OX1/2 receptors and GAP junction modulators. Neil is the author of several patents, continues to publish and support the educational efforts of the British Pharmacological Society of which he is a Fellow.

Massimiliano (Max) Bianchi PhD

Max joined Transpharmation in January 2014 as General Manager of the Irish subsidiary Transpharmation Ireland Ltd, a Campus Company at the Trinity College Dublin – Institute of Neuroscience (TCIN)

Max joined Transpharmation in January 2014 as General Manager of the Irish subsidiary Transpharmation Ireland Ltd, a Campus Company at the Trinity College Dublin – Institute of Neuroscience (TCIN). Dr. M. Bianchi has 15 years of research experience on neuropharmacology, neuronal plasticity and drug discovery. He has been associated for six years with the former Psychiatry Centre of Excellence for Drug Discovery of GlaxoSmithKline (Psychiatry CEDD-GSK). During such period Max successfully completed is PhD on the neuropsychopharmacology of cytoskeletal microtubules (University of Nottingham, UK) and worked as scientist in the Neurochemistry team of the Psychiatry CEDD-GSK. He managed an innovative project of target validation showing that animal models of depression and antidepressant drugs can influence neuronal plasticity and the expression and function of specific microtubular proteins. He then joined the French Biotech MAPREG in 2007 to establish and lead a new psychopharmacology unit. He designed and successfully managed an innovative drug discovery EU granted project (Eurostars/Eureka) named DEPSTER (E!5291): “The pregnenolone-derivative 3beta-methoxy-pregnenolone as a new therapy for the treatment of depressive disorders: a preclinical project”. Max’s innovative experimental approaches are multidisciplinary and couples animal models, behavioural assays, molecular biology and experimental medicine.
About
News
The Management
Facilities
Ethical compliance

Publications

We are constantly looking for novel preclinical/clinical assays, technologies and endpoints that increase your success. Wherever possible we strive to publish our research in peer reviewed journals.

icon_techTechnology

A CRO should offer technologies you do not have in your own company. Investment in technology, bringing capabilities together, underpins our desire to innovate & produce multiple endpoints to a single study.